{"id":9902,"date":"2021-05-19T11:43:48","date_gmt":"2021-05-19T18:43:48","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9902"},"modified":"2021-05-20T11:44:26","modified_gmt":"2021-05-20T18:44:26","slug":"effectiveness-of-bnt162b2-mrna-vaccine-and-chadox1-adenovirus-vector-vaccine-on-mortality-following-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/19\/effectiveness-of-bnt162b2-mrna-vaccine-and-chadox1-adenovirus-vector-vaccine-on-mortality-following-covid-19\/","title":{"rendered":"Effectiveness of BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Mortality Following COVID-19"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Even in the small percentage of vaccine recipients who develop symptomatic disease, vaccination with either the Pfizer-BionNTech vaccine or the Oxford-AztraZeneca vaccine conferred additional protection against death, according to analysis of data from England. Among adults aged \u226570 years with COVID-19, those vaccinated with 1 dose of the Pfizer-BioNTech vaccine, 1 dose of Oxford-AstraZeneca vaccine, and 2 doses of the Pfizer-BioNTech vaccine had a 44%, 55%, and 69% reduced risk of death, respectively, compared to unvaccinated adults according to an analysis of 48,096 cases with at least 28 days of follow-up. The protection from death conferred by vaccines is additional to conferred protection against COVID-19. Reductions in risk were similar by age group; however, care home residents had a smaller reduction in risk of death after 1 dose of the Pfizer-BioNTech vaccine compared to non-care home residents (13% vs 52%), but a larger reduction in risk of death after 1 dose of the Oxford-AstraZeneca vaccine (63% vs 48%).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Bernal et al.\u00a0(May 18, 2021). Effectiveness of BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Mortality Following COVID-19. Pre-print downloaded May 19 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.14.21257218\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.14.21257218<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Even in the small percentage of vaccine recipients who develop symptomatic disease, vaccination with either the Pfizer-BionNTech vaccine or the Oxford-AztraZeneca vaccine conferred additional protection against death, according to analysis of data from England. Among adults aged \u226570 years with COVID-19, those vaccinated with 1 dose of the Pfizer-BioNTech vaccine, 1 dose&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/19\/effectiveness-of-bnt162b2-mrna-vaccine-and-chadox1-adenovirus-vector-vaccine-on-mortality-following-covid-19\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-9902","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9902"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9902\/revisions"}],"predecessor-version":[{"id":9903,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9902\/revisions\/9903"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9902"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}